FDA Kicks Off 510(k) Reform Plan, Punts Some Decisions To IOM
This article was originally published in The Gray Sheet
Executive Summary
FDA’s plan for improving its 510(k) pre-market submission program includes clarifying instances where clinical data should be included and streamlining its “de novo” review process for certain innovative, lower-risk devices.
You may also be interested in...
FDA Claims Short-Term Success For Pre-Market Device Reforms
With many of its 510(k) and science reforms at least partially implemented, CDRH says it is seeing tangible, positive results. The device center cites a turnaround on multiple measures of review performance following the lows of 2010.
CDRH Drops Seven Divisive 510(k) Proposals; Congress Picks Some Up
The device center is dropping seven controversial 510(k) reform-related proposals, including creating a “class IIb” category of devices, following pushback from industry. But some of the matters are under consideration on Capitol Hill.